Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI model aims to predict surgery risks for stomach cancer patients

NCT ID NCT07401173

Diagnosis Sponsor: Qun Zhao Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing an artificial intelligence tool called DeepComp that uses CT scans and patient data to predict which stomach cancer patients are at high risk for major complications after surgery. Researchers will enroll 500 patients across five medical centers and compare the AI's predictions with what actually happens within 30 days after surgery. If accurate, this could help doctors plan better care and reduce risks for patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
DeepComp AI model (multimodal deep learning radiomics)
What this could lead to
If successful, this AI tool could help doctors identify high-risk patients before surgery, allowing for better preparation and personalized care to reduce complications.
What could go wrong
This is an observational study, not a treatment trial. The AI model may not be accurate enough in real-world settings, and results may not apply to all patients or hospitals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

May 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients diagnosed with potentially resectable gastric cancer who are admitted to the participating centers for surgical treatment.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Age ≥ 18 years. Histologically confirmed gastric adenocarcinoma. Scheduled for elective radical gastrectomy (open, laparoscopic, or robotic) with curative intent. Standard preoperative contrast-enhanced abdominal CT scans (venous phase) performed within 14 days prior to surgery. Willingness to sign informed consent. Exclusion Criteria: Emergency surgery due to perforation, obstruction, or massive bleeding. Intraoperative findings of distant metastasis (Stage IV) or unresectable disease preventing R0 resection. Concurrent or previous malignant tumors within the last 5 years (except gastric cancer). Pregnancy or lactation. Severe metallic artifacts on CT images preventing radiomic analysis.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastric adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

disease gastric adenocarcinoma gastric cancer gastric neoplasm Postoperative Complications

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gastric cancer (diagnosis) Postoperative complications

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • the Fourth Hospital of Hebei Medical University

    RECRUITING

    Shijiazhuang, None Selected, 050011, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.